Herein, we observed that the trastuzumab resistant HER2+/ER+ breast cancer cells displayed a shift in oncogene addiction away from HER2 to TFF3 with highly upregulated TFF3 expression and downregulated HER signalling. Here, ERBB2 is linked to breast carcinoma.